Supplementary Figure S2 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Year: 2024
Type: supplementary-materials
Abstract: CfDNA concentration in patients with HER2-negative breast cancers. CfDNA concentration was measured in the plasma of patients with hormone receptor-positive HER2-negative (HR+HER2-) and triple-negative breast cancer (TNBC). P values were calculated using the Wilcoxon rank sum test. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).
Authors: Mark Jesus M. Magbanua, Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Jane Perlmutter, Paula Pohlmann, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van 't Veer
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4399297978